undamentalytics Newsletter

Link William J Phd: insider trades

Director at 4 companies we cover. No open-market purchases and 11 sales not made under a pre-set plan, reported from June 2, 2016 to September 10, 2025.

What happened after Link William J Phd’s sales?

After their sales, the shares moved +5.0% against the index over 12 months on average (a negative figure means selling was the right call); 46% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

Trade by trade

Link William J Phd: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 0 — — — — — — Not enough years
Purchases, 6 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the trade 0 — — — — — — Not enough years
Sales, 3 months after the report 11 +21.3% +16.2% 0% 6 2.88 0.035 Some evidence: seller wrong
Sales, 12 months after the report 11 +5.0% +13.9% 46% 6 −0.03 0.98 No reliable evidence
Sales, 12 months after the trade 11 +7.1% +17.4% 46% 6 −0.02 0.98 No reliable evidence

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Glaukos Corp GKOS —04June 2, 2016December 3, 2020
Edwards Lifesciences EW —04December 1, 2016August 21, 2019
Tarsus Pharmaceuticals, Inc. TARS —02August 14, 2024September 10, 2025
Rxsight, Inc. RXST —01February 2, 2024February 2, 2024

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
September 10, 2025September 8, 2025 TARS Sale $1,545,612 +51.9%+37.2%+26.7%
August 14, 2024August 12, 2024 TARS Sale $912,961 +64.2%+82.1%+84.1%
February 2, 2024February 1, 2024 RXST Sale $1,403,101 +29.4%−52.8%−56.3%
December 3, 2020December 1, 2020 GKOS Sale $3,398,456 +16.2%−66.8%−63.4%
August 21, 2019August 20, 2019 EW Sale $2,266,116 +5.9%−9.5%−12.1%
November 20, 2018November 19, 2018 EW Sale $2,035,544 +7.4%+42.8%+45.2%
November 15, 2018November 13, 2018 GKOS Sale $2,391,172 +8.9%−14.1%−5.4%
February 13, 2018February 9, 2018 EW Sale $1,466,868 +3.4%+31.7%+33.8%
December 1, 2016November 29, 2016 EW Sale $1,260,150 +0.1%+13.9%+17.4%
November 18, 2016November 17, 2016 GKOS Sale $1,013,400 +29.7%−42.7%−41.5%
June 2, 2016May 31, 2016 GKOS Sale $816,711 +17.3%+33.5%+49.8%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Link William J Phd traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.